Arcus Biosciences (RCUS)
(Delayed Data from NYSE)
$9.23 USD
+0.07 (0.76%)
Updated Aug 4, 2025 04:00 PM ET
After-Market: $9.23 0.00 (0.00%) 6:18 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
Arcus Biosciences, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
RCUS 9.23 +0.07(0.76%)
Will RCUS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RCUS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RCUS
Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Lags Revenue Estimates
Arcus Biosciences, Inc. (RCUS) Reports Q4 Loss, Tops Revenue Estimates
RCUS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Moderna (MRNA) Stock Jumps 11.7%: Will It Continue to Soar?
Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Tops Revenue Estimates
Regeneron (REGN) Tops Q3 Earnings and Revenue Estimates
Other News for RCUS
Arcus Biosciences Inc (RCUS) Announces Equity Awards for New Employee | RCUS stock news
Arcus Biosciences Announces New Employment Inducement Grants | RCUS Stock News
Arcus Biosciences (RCUS) Gains FDA Orphan Drug Status for Pancreatic Cancer Treatment
Arcus says Gilead-partnered cancer drug won FDA orphan status
Arcus Biosciences’ cancer drug gets orphan drug status